You are viewing an expired study

Central Contact Ft. Worth, Texas 76134

  • Macular Degeneration


The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.


Inclusion Criteria: - Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Other protocol-defined exclusion criteria may apply.



Primary Contact:

Study Director
Terry Wiernas, PhD
Alcon Research

Backup Contact:


Location Contact:

Central Contact Ft. Worth, Texas 76134
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.